Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Corcept Therapeutics Inc | 3.6B | 30.6x | +9.80% |
Harmony Biosciences Holdings Inc | 2.1B | 18.6x | --- |
Amphastar Pharmaceuticals Inc | 2.3B | 15.3x | --- |
ANI Pharmaceuticals Inc | 1.3B | 51.9x | -8.16% |
HUTCHMED (China) Ltd | 3.0B | -69.1x | --- |
Collegium Pharmaceutical Inc | 1.2B | 16.5x | --- |
Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.6B |
---|---|
Revenue (TTM) | $569.6M |
Shares Outstanding | 104.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.45 |
EPS | $1.14 |
Book Value | $4.90 |
P/E Ratio | 30.6x |
Price/Sales (TTM) | 6.4 |
Price/Cash Flow (TTM) | 28.6x |
Operating Margin | 22.46% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.